Literature DB >> 11976023

Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate.

Al-Sayed Sallam1, Enam Khalil, Hussain Ibrahim, Ibtisam Freij.   

Abstract

Glyceryl monooleate is a Food and Drug Administration-approved food additive which has the ability to form various liquid crystalline phases in the presence of various amounts of water. The unique properties of the cubic liquid crystalline phase that result upon the presence of excess body fluids at body temperature were utilized to formulate an oral dosage form containing furosemide as the model drug. The aim was to develop a formula, which has both bioadhesive and sustained release properties of the resultant cubic phase, so that increasing gastric residence time to improve bioavailability of the drug and at the same time obtaining a sustained action. The system was found to be affected by the limited solubility of furosemide in both the carrier system and the pH of surrounding medium. As a consequence, the addition of some solubility modifiers was investigated in order to obtain the desired properties of the expected liquid crystalline system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976023     DOI: 10.1016/s0939-6411(02)00016-4

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  12 in total

1.  Preparation and characterization of pluronic-colloidal silicon dioxide composite particles as liquid crystal precursor.

Authors:  Manish Maheshwari; Anant Paradkar; Shigeo Yamamura; Shivajirao Kadam
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

2.  Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.

Authors:  Eder André Estracanholli; Fabíola Silva Garcia Praça; Ana Beatriz Cintra; Maria Bernadete Riemma Pierre; Marilisa Guimarães Lara
Journal:  AAPS PharmSciTech       Date:  2014-07-01       Impact factor: 3.246

Review 3.  Liquid Crystalline Phases for Enhancement of Oral Bioavailability.

Authors:  Xingwang Zhang; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2021-02-22       Impact factor: 3.246

4.  Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration.

Authors:  Tri-Hung Nguyen; Tracey Hanley; Christopher J H Porter; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2011-12       Impact factor: 4.617

5.  Glyceryl monooleate-coated bioadhesive hollow microspheres of riboflavin for improved gastroretentivity: optimization and pharmacokinetics.

Authors:  Mayank Shekhar Upadhyay; Kamla Pathak
Journal:  Drug Deliv Transl Res       Date:  2013-06       Impact factor: 4.617

6.  Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability.

Authors:  Zhiwen Yang; Yinhe Tan; Meiwan Chen; Linghui Dian; Ziyun Shan; Xinsheng Peng; Chuanbin Wu
Journal:  AAPS PharmSciTech       Date:  2012-10-23       Impact factor: 3.246

Review 7.  Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.

Authors:  Karin Becker; Sharareh Salar-Behzadi; Andreas Zimmer
Journal:  Pharm Res       Date:  2015-03-19       Impact factor: 4.200

Review 8.  Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals.

Authors:  Rajan Rajabalaya; Muhammad Nuh Musa; Nurolaini Kifli; Sheba R David
Journal:  Drug Des Devel Ther       Date:  2017-02-13       Impact factor: 4.162

9.  Bioadhesive floating microsponges of cinnarizine as novel gastroretentive delivery: Capmul GMO bioadhesive coating versus acconon MC 8-2 EP/NF with intrinsic bioadhesive property.

Authors:  Smita Raghuvanshi; Kamla Pathak
Journal:  Int J Pharm Investig       Date:  2016 Oct-Dec

Review 10.  Cubic and hexagonal liquid crystals as drug delivery systems.

Authors:  Yulin Chen; Ping Ma; Shuangying Gui
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.